Biotechnology Innovation Organization’s Post

I recently came across an article detailing the top takeaways from 2024's Swiss Biotech Day conference. What was number 1? Early partnerships. Richard Girling and other experts highlighted that early-stage deals gave biotech companies the tools they needed to improve their dealmaking abilities in later stages. When we consider that companies will have to engage in more M&A deals to maintain growth, the benefits of early partnerships become even more important. Read the article here: https://lnkd.in/er7cv3RG #Biotech #Partnerships #MandA #Growth

Coming out of the Biocom California CEO Summit, I share biotech investor predictions and CEO insights in the latest edition of Vital Signs: https://lnkd.in/ghXYRsaq

As development cost and complexity continue to increase, it is more important than ever for biotech to be more intentional with the deployment of the funds they secure. In part two of our biotech funding whitepaper series, we share practical considerations to improve asset development programs across operational strategies, acceleration, regulatory, value-building and partnership aspects. https://ow.ly/uyH350RrYLy

Cantor's list of "Biotech's Resilient Angels": 5 of them got acquired "The industry fluctuates b/w practice-changing breakthroughs & devastating setbacks, creating a high-risk, high-reward environment for investors & companies alike" Today, 126 of 700 Biotechs trading below cash

Our recent webinar, Enhancing Investor Confidence with Robust Biostatistics, is now available on our website. Enjoy 60 minutes of insightful discussions, including why CMO's should build strong relationships with biostatisticians to boost investor confidence, what investors look for in biotech clinical development plans and an outlook on the current biotech market. Our CEO, Aiden Flynn, is joined by experts Victoria Manax Rutson, MD, a seasoned CMO and investor, and Susan Clement Davies, a life sciences financier with over 25 years in capital markets and investment banking, and a valued member of Exploristics' board. Watch now: https://lnkd.in/e59n5PT9 View our biotech funding case study referenced here: https://lnkd.in/esk3Pu_A #Biostatistics #InvestorConfidence #Biotech #LifeSciences #CMOLeadership #InvestmentStrategies #DataDrivenDecisions #CapitalMarkets #Biotechnology

To my biotech network, last week, we hosted an incredible panel discussion with industry leaders in Investment and Biostatistics, featuring Aiden Flynn, Susan Clement Davies, and Victoria Manax Rutson, MD. Tune in to learn how Biostatistics plays a vital role in securing investor confidence when seeking funding in the biotech space. Listen in and gain valuable insights! #biotech #investment #biostatistics

Optimising operations will help biotechs facilitate movement through critical milestones, avoid delays and help navigate this most difficult program phase. Learn how biotech sponsors can mitigate costly, time-consuming changes by simplifying protocol design in part two of our biotech funding whitepaper series. https://ow.ly/ZyUc50RrXHn

🔬✨ Could Soligenix (SNGX) be the next big winner in biotech? 🤔 In our latest video, we dive deep into their groundbreaking HyBryte study and explore the future potential of this innovative biopharma company. 🚀💡 Discover Soligenix's recent achievements, upcoming milestones, and why HyBryte stands out as a promising treatment in the biotech landscape. 🌟🔍 Join us as we analyze the key factors that could drive Soligenix's growth and find out if SNGX stock is a smart investment for the future. 📈💰 Watch now to get the inside scoop! 🎥 https://lnkd.in/dHArNM8R

The volume of transactions in the #biotech sphere this year is on par with last year, but the total deal value is way off, writes Adam Feuerstein. Here are some numbers: ➡️ 2024 is on course to be the worst biotech M&A year since 2021, based on total deal value. ➡️ The largest deal this year — $4.9 billion paid by Vertex Pharma for Alpine Immune Sciences — would have been the ninth largest in 2023. ➡️ Only 14 of the 35 acquired companies on Adam's 2024 list were publicly traded — a big dropoff from previous years. Now the fun stuff - what are some possible takeover targets? Read on: https://trib.al/4y3IszW

A central part of the founder-led biotech revolution: In the middle of a technological paradigm shift, it's important to back new founders with new ideas! Great quote by Tony Kulesa in a new article on the resurgence of the founder-led movement: https://lnkd.in/gxFT8mvG